Boston Scientific (NYSE:BSX) Given New $48.00 Price Target at Needham & Company LLC

Key Points

• Needham cut Boston Scientific’s price target from $57 to $48 while maintaining a “buy” rating, implying about 11% upside from the prior close. The broader analyst consensus remains “Moderate Buy,” with an average target of $65.63.
• Boston Scientific’s latest results modestly exceeded expectations, with quarterly EPS of $0.73 versus $0.72 expected and revenue of $5.14 billion versus approximately $5.06 billion expected.
• Near-term concerns remain: the company reduced its 2026 outlook after a cybersecurity incident disrupted operations, while shares fell 4% to $43.26 and traded near their 52-week low, below key moving averages.

Boston Scientific (NYSE:BSX - Get Free Report) had its price target decreased by analysts at Needham & Company LLC from $57.00 to $48.00 in a report released on Wednesday, Benzinga reports. The brokerage presently has a "buy" rating on the medical equipment provider's stock. Needham & Company LLC's target price would suggest a potential upside of 10.96% from the company's previous close.

A number of other equities analysts have also weighed in on the stock. JPMorgan Chase & Co. dropped their target price on shares of Boston Scientific from $80.00 to $56.00 and set an "overweight" rating for the company in a research report on Thursday, July 30th. Evercore reduced their target price on Boston Scientific from $65.00 to $52.00 and set an "outperform" rating on the stock in a report on Wednesday, October 7th. Wall Street Zen lowered Boston Scientific from a "buy" rating to a "hold" rating in a research note on Sunday, August 2nd. Weiss Ratings reaffirmed a "sell (d+)" rating on shares of Boston Scientific in a report on Friday, October 2nd. Finally, Royal Bank Of Canada cut their target price on shares of Boston Scientific from $85.00 to $70.00 and set an "outperform" rating for the company in a report on Thursday, July 30th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $65.63.

Boston Scientific Stock Down 4.0%

Shares of NYSE:BSX traded down $1.80 during trading on Wednesday, reaching $43.26. 39,136,456 shares of the stock traded hands, compared to its average volume of 18,518,668. Boston Scientific has a 52-week low of $39.57 and a 52-week high of $105.65. The stock has a 50-day moving average of $45.29 and a two-hundred day moving average of $57.71. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24. The stock has a market cap of $62.69 billion, a P/E ratio of 17.55, a price-to-earnings-growth ratio of 1.10 and a beta of 0.58.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its earnings results on Wednesday, October 28th. The medical equipment provider reported $0.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.01. The company had revenue of $5.14 billion for the quarter, compared to analysts' expectations of $5.06 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The firm's quarterly revenue was up 1.4% on a year-over-year basis. During the same quarter last year, the company posted $0.75 earnings per share. As a group, sell-side analysts expect that Boston Scientific will post 3.21 earnings per share for the current fiscal year.

Insider Buying and Selling at Boston Scientific

In related news, Director Edward J. Ludwig bought 5,000 shares of the stock in a transaction on Friday, July 31st. The stock was bought at an average price of $45.48 per share, for a total transaction of $227,400.00. Following the completion of the acquisition, the director directly owned 30,359 shares in the company, valued at approximately $1,380,727.32. This represents a 19.72% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director David C. Habiger acquired 2,100 shares of the company's stock in a transaction that occurred on Wednesday, August 5th. The shares were bought at an average cost of $47.59 per share, for a total transaction of $99,939.00. Following the transaction, the director owned 17,160 shares of the company's stock, valued at $816,644.40. This represents a 13.94% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have acquired 194,522 shares of company stock valued at $9,385,210 in the last quarter. 0.34% of the stock is owned by insiders.

Institutional Trading of Boston Scientific

Large investors have recently bought and sold shares of the stock. BlackRock Inc. acquired a new stake in Boston Scientific during the 2nd quarter valued at approximately $5,534,781,000. Primecap Management Co. CA purchased a new stake in Boston Scientific in the 2nd quarter worth $2,156,233,000. Janus Henderson Group PLC raised its holdings in shares of Boston Scientific by 31.0% during the first quarter. Janus Henderson Group PLC now owns 16,497,366 shares of the medical equipment provider's stock valued at $1,035,202,000 after acquiring an additional 3,907,981 shares during the last quarter. Amundi raised its holdings in Boston Scientific by 13.8% in the 1st quarter. Amundi now owns 14,122,913 shares of the medical equipment provider's stock valued at $886,213,000 after acquiring an additional 1,707,754 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership grew its holdings in Boston Scientific by 25.9% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 13,891,668 shares of the medical equipment provider's stock valued at $871,702,000 after buying an additional 2,856,040 shares in the last quarter. Hedge funds and other institutional investors own 89.07% of the company's stock.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific reported third-quarter adjusted earnings of $0.73 per share, slightly above the $0.72 consensus estimate, while revenue of $5.138 billion also exceeded expectations of approximately $5.06 billion. Boston Scientific third-quarter earnings report
• Positive Sentiment: Management highlighted longer-term potential, targeting a business-cycle trough in 2027 and expansion toward 2030. The company also began enrollment in its Elite AF clinical trial and received FDA clearances for StoneSmart technologies and an expanded SEISMIQ catheter offering. Boston Scientific third-quarter results announcement
• Neutral Sentiment: Third-quarter reported sales increased 1.5% year over year to $5.138 billion, but adjusted EPS declined from $0.75 to $0.73 and GAAP EPS fell from $0.51 to $0.40. Cardiovascular sales rose 1.9%, while MedSurg sales grew only 0.6%; regional performance was mixed.
• Negative Sentiment: Boston Scientific again reduced its fiscal-year 2026 outlook after a cybersecurity incident disrupted operations and weighed on demand. Management now expects approximately 4.25% reported sales growth for the year and forecasts fourth-quarter reported and organic sales declines of 1% to 3%. Boston Scientific outlook and cybersecurity report
• Negative Sentiment: The cybersecurity fallout, other operating headwinds and lower guidance overshadowed the earnings and revenue beats. The stock was trading near its 52-week low and below both its 50-day and 200-day moving averages, reflecting continued investor concern about near-term execution and growth.

Boston Scientific Company Profile

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.